Interleukin Genetics names new CEO

Previously, Mr. Bender was chief technology officer and interim CEO of Emisphere Technologies, a biopharmaceutical company. The company expects to add Mr. Bender to its board of directors prior to the board’s next regularly scheduled meeting. Thomas Curran, Jr., who served as interim CEO since July 2007, will continue to serve as a member of Interleukin’s board of directors.

James Weaver, chairman of the board, Interleukin, said: “Lew’s extensive background in business development, technology management and the creation of value-added partnerships with leading companies across the pharma sector will be important assets as our company moves forward.”